{
    "doi": "https://doi.org/10.1182/blood.V116.21.1360.1360",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1738",
    "start_url_page_num": 1738,
    "is_scraped": "1",
    "article_title": "Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial ",
    "article_date": "November 19, 2010",
    "session_type": "CLL - Biology and Pathophysiology, excluding Therapy: Poster I",
    "topics": [
        "b-lymphocytes",
        "chronic b-cell leukemias",
        "chronic lymphocytic leukemia",
        "lymphocytosis",
        "zap-70 kinase",
        "alemtuzumab",
        "trisomy 12",
        "chromosome abnormality",
        "treatment outcome",
        "lymphocytes"
    ],
    "author_names": [
        "Stefano Molica",
        "Sonia Fabris, PhD",
        "Giovanna Cutrona, PhD",
        "Serena Matis, PhD",
        "Emanuela Anna Pesce",
        "Francesco Maura",
        "Gabriella Ciceri",
        "Francesco Di Raimondo",
        "Caterina Musolino, MD",
        "Marco Gobbi, MD",
        "Nicola Di Renzo, MD",
        "Francesca Romana Mauro, MD",
        "Renato Cantaffa",
        "Maura Brugiatelli, MD",
        "Francesco Merli, MD",
        "Simonetta Zupo",
        "Caterina Mammi",
        "Luca Baldini, MD",
        "Francesco Angrilli, MD",
        "Gianni Quintana",
        "Ugo Consoli, MD",
        "Emilio Iannitto",
        "Paolo Di Tonno",
        "Alberto Fragasso",
        "Pellegrino Musto",
        "Maria Cristina Cox",
        "Gainluca Festini",
        "Vincenzo Callea, MD",
        "Stefano Sacchi",
        "Agostino Cortelezzi, MD",
        "Giorgio Lambertenghi Deliliers",
        "Robin Foa\u0300, MD",
        "Massimo Federico, MD",
        "Antonino Neri, MD",
        "Manlio Ferrarini",
        "Fortunato Morabito, MD"
    ],
    "author_affiliations": [
        [
            "Henatology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "GISL Trial Office, Modena, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Division of Hematology, Ospedale Ferrarotto, Catania, Italy, "
        ],
        [
            "University of Messina, Hematology Section, Messina, Italy, "
        ],
        [
            "Chair of Haematology, University of Genova, Genova, "
        ],
        [
            "Unita\u0300 di Ematologia, Ospedale Vito Fazzi, Lecce, Italy, "
        ],
        [
            "Department of Cellular Biotechnologies and Hematology, \u201cSapienza\u201d University, Rome, Italy, "
        ],
        [
            "Divisione di Ematologia, Azienda Ospedaliera Catanzaro, Catanzaro, Italy, "
        ],
        [
            "Azienda Ospedaliera Papardo, Divisione Di Ematologia, Messina, Italy, "
        ],
        [
            "Hematology, Azienda Ospedaliera S.Maria Nuova, Reggio Emilia, Italy, "
        ],
        [
            "SS Malattie Linfoproliferative, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Unita\u0300 Operativa di Ematologia, A.O.S. Maria Nuova, Reggio Emilia, Italy, "
        ],
        [
            "U.O. Ematologia 1 - Centro CTMO, Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milano, Italy, "
        ],
        [
            "Hematology, Pescara, Italy, "
        ],
        [
            "Divisione di Ematologia, Presidio Ospedaliero A.Perrino, Brindisi, Italy, "
        ],
        [
            "Oncology, Divisione di Ematologia, Ospedale Garibaldi Nesima, Catania, Italy, Catania, Italy, "
        ],
        [
            "Department of Hematology, University of Palermo, Palermo, Italy, "
        ],
        [
            "Dipartimento di Ematologia,Venere, Ospedale Bari Carbonara, Bari, "
        ],
        [
            "Ospedale di Matera, Matera, Jamaica, "
        ],
        [
            "Italian Multiple Myeloma Network, GIMEMA, Italy, Italy, "
        ],
        [
            "Ematologia, A.O. Sant'Andrea, Universita' La Sapienza, Roma, Italy, "
        ],
        [
            "Centro di Riferimento Ematologico-Seconda Medicina, Azienda Ospedaliero-Universitaria, Ospedali Riuniti, Trieste, Italy, "
        ],
        [
            "Institute of Hematology- Reggio Calabria, Italy, Italy, "
        ],
        [
            "Oncologia ed Ematologia, Universita\u0300 di Modena, Modena, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Division of Hematology 1/CTMO, Fondazione IRCCS Ca\u0300 Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, "
        ],
        [
            "Institute of Hematology, Department of Cellular Biotechnologies and Hematology, \u201cSapienza\u201d University of Rome, Roma, Italy, "
        ],
        [
            "Dip. Integrato di Onc./Em., Centro Oncologico Modenese, Modena, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Cosenza Hospital, Hematology Section, Cosenza, Italy"
        ]
    ],
    "first_author_latitude": "38.9202449",
    "first_author_longitude": "16.5823473",
    "abstract_text": "Abstract 1360 The arbitrary cut-off of 5000/\u03bcL chronic lymphocytic leukemia (CLL)-phenotype cells in peripheral blood is generally used to separate monoclonal B-cell lymphocytosis (MBL) from CLL. However, a major concern is the biological differentiation, if any, between MBL and CLL. We tried to address the issue therefore analyzing 261 Rai stage 0 patients enrolled in a Gruppo Italiano Studio Linfomi (GISL) prospective multicentre trial designed to validate biological parameters in early CLL as well as to assess the impact on clinical outcome of an early versus delayed policy of treatment with subcutaneous alemtuzumab in the high biological risk. In this cohort, biological characteristics of 105 (40.2%) patients who would be reclassified as MBL using the 2008 CLL diagnostic criteria were compared with those of the remaining 156 patients who had more than 5000/\u03bcL CLL-phenotype cells in peripheral blood and fulfilled diagnostic criteria of CLL. Male to female ratio was similar for MBL and CLL (54/53 vs. 92/66, P=0.21) as was median age (58.18 vs 58.18, P=0.98). Median absolute number of cells with CLL phenotype in peripheral blood was 3120/\u03bcL (range,400-4959) in MBL and 9925/\u03bcL (range, 5020\u2013110000) in CLL (P<0.0001). No difference in the CD38 status (P=0.48),ZAP-70 expression (P=0.29) or cytogenetic abnormalities as detected by FISH [trisomy 12 (P=0.24); deletion 11q (P=0.68); del17p (P=0.09)] was found between patients with MBL and CLL. The only feature differentiating CLL from MBL was represented by an excess of patients with unmutated IgVH disease in the former group (CLL,69.2% vs. MBL, 30.8%: P=0.04). In addition, patients with CLL had an about 2-fold risk of having IgVH germline status in comparison to patients with MBL (OR,1.80; 95% CI, 1.02\u20133.13; P=0.04). Since the arbitrary cut-off of 5000/\u03bcL CLL-phenotype cells in peripheral blood failed to identify a peculiar biological profile for either MBL or CLL, we wondered whether a different B-cell threshold based on disease clinical outcome better stratified patients according to biological risk. In an independent cohort including 818 Rai stage 0 patients registered in a GIMEMA (Gruppo Italiano Malattie EMatologiche Maligne dell'Adulto) database, we demonstrated that a count of 10000/ \u03bcL B-cells is the best lymphocyte threshold to predict time to first therapy (TFT). When this cut-off was applied to the GISL series we found that the distribution of main high-risk features [CD38, P=0.83; trisomy 12,P=0.36; del11q,P=0.85; del17,P=0.37) was similar between patients with B-cell lymphocytes higher and lower than 10000/ \u03bcL. Only an excess of cases with unmutated IgVH (P=0.04) and slightly increase of ZAP-70 (P=0.06) characterized patients B-cell higher than 10000 \u03bcL. In conclusion, present data obtained from a prospective multicentre study indicate that biological characteristics of CLL are found also in MBL and there is no general predominance of good risk variables in MBL in comparison to CLL. This implies that MBL may not be considered a distinct disease but as an early stage of CLL. Disclosures: Musto: Celgene: Honoraria; Janssen Cilag: Honoraria."
}